I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding ...

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $200 billion by market cap, the company delivers health solutions through its prescription medicines ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to buy according to billionaires. Some experts view medical, healthcare ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average. Supported by world-class markets data from ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein(a), or Lp ...

Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...